A
Alexa S. Green
Researcher at Paris Descartes University
Publications - 33
Citations - 2353
Alexa S. Green is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Myeloid leukemia & PI3K/AKT/mTOR pathway. The author has an hindex of 19, co-authored 33 publications receiving 2103 citations. Previous affiliations of Alexa S. Green include Centre national de la recherche scientifique & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park,Nicolas Chapuis,Jerome Tamburini,Valérie Bardet,Pascale Cornillet-Lefebvre,Lise Willems,Alexa S. Green,Patrick Mayeux,Catherine Lacombe,Didier Bouscary +9 more
TL;DR: The results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).
Journal ArticleDOI
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Lise Willems,Lise Willems,Nathalie Jacque,Arnaud Jacquel,Nathalie Neveux,Thiago Trovati Maciel,Mireille Lambert,Alain Schmitt,Laury Poulain,Alexa S. Green,Madalina Uzunov,Olivier Kosmider,Olivier Kosmider,Isabelle Radford-Weiss,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Valérie Bardet,Valérie Bardet,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Jerome Tamburini,Didier Bouscary,Didier Bouscary +28 more
TL;DR: It is shown that glutamine removal inhibits mTORC1 and induces apoptosis in AML cells, and that l-ases upregulate glutamine synthase expression in leukemic cells and that a GS knockdown enhances l-ase-induced apoptotic response in someAML cells.
Journal ArticleDOI
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Jerome Tamburini,Jerome Tamburini,Alexa S. Green,Alexa S. Green,Valérie Bardet,Valérie Bardet,Nicolas Chapuis,Nicolas Chapuis,Sophie Park,Sophie Park,Lise Willems,Lise Willems,Madalina Uzunov,Norbert Ifrah,François Dreyfus,François Dreyfus,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Didier Bouscary +21 more
TL;DR: It is shown here that the translation inhibitor 4EGI-1 decreased the clonogenic growth of leukemic progenitors and induced apoptosis of blast cells, with limited toxicity against normal hematopoiesis, which emphasize the importance of translation deregulation in acute myeloid leukemia (AML) biology.
Journal ArticleDOI
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Alexa S. Green,Alexa S. Green,Nicolas Chapuis,Nicolas Chapuis,Thiago Trovati Maciel,Lise Willems,Lise Willems,Mireille Lambert,Mireille Lambert,Christophe Arnoult,Olivier Boyer,Valérie Bardet,Valérie Bardet,Sophie Park,Marc Foretz,Marc Foretz,Benoit Viollet,Benoit Viollet,Norbert Ifrah,François Dreyfus,Olivier Hermine,Ivan C. Moura,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Jerome Tamburini +27 more
TL;DR: The induction of the LKB1/AMPK/TSC tumor suppressor axis is functional in AML and can be activated by the biguanide molecule metformin, resulting in a specific inhibition of mammalian target of rapamycin catalytic activity.
Journal ArticleDOI
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis,Jerome Tamburini,Alexa S. Green,Christine Vignon,Valérie Bardet,Aymeric Neyret,Melanie Pannetier,Lise Willems,Sophie Park,Alexandre Macone,Sauveur-Michel Maira,Norbert Ifrah,François Dreyfus,Olivier Herault,Catherine Lacombe,Patrick Mayeux,Didier Bouscary +16 more
TL;DR: NVP-BEZ235 reduces the proliferation rate and induces an important apoptotic response in AML cells without affecting normal CD34+ survival and therefore represents a promising option for future AML therapies.